Thomas Tray - Net Worth and Insider Trading
Thomas Tray Net Worth
The estimated net worth of Thomas Tray is at least $1 Million dollars as of 2023-03-28. Thomas Tray is the Principal Accounting Officer of Incyte Corp and owns about 16,606 shares of Incyte Corp (INCY) stock worth over $1 Million. Details can be seen in Thomas Tray's Latest Holdings Summary section.
Transaction Summary of Thomas Tray
Thomas Tray Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Thomas Tray owns 1 companies in total, including Incyte Corp (INCY) .
Click here to see the complete history of Thomas Tray’s form 4 insider trades.
Insider Ownership Summary of Thomas Tray
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| INCY | Incyte Corp | 2022-03-11 | Principal Accounting Officer |
Thomas Tray Latest Holdings Summary
Thomas Tray currently owns a total of 1 stock. Thomas Tray owns 16,606 shares of Incyte Corp (INCY) as of December 19, 2022, with a value of $1 Million.
Latest Holdings of Thomas Tray
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| INCY | Incyte Corp | 2022-12-19 | 16,606 | 70.31 | 1,167,568 |
Holding Weightings of Thomas Tray
Thomas Tray Form 4 Trading Tracker
According to the SEC Form 4 filings, Thomas Tray has made a total of 2 transactions in Incyte Corp (INCY) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Incyte Corp is the sale of 1,223 shares on December 19, 2022, which brought Thomas Tray around $100,482.
Insider Trading History of Thomas Tray
- 1
Thomas Tray Trading Performance
Thomas Tray Ownership Network
Ownership Network List of Thomas Tray
Ownership Network Relation of Thomas Tray
Thomas Tray Owned Company Details
What does Incyte Corp do?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Who are the key executives at Incyte Corp?
Thomas Tray is the Principal Accounting Officer of Incyte Corp. Other key executives at Incyte Corp include EVP & Head of Tech. Operations Michael James Morrissey , EVP & General Manager & Europe Jonathan Elliott Dickinson , and EVP & Chief Financial Officer Christiana Stamoulis .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Thomas Tray made 2 insider transaction in Incyte Corp (INCY) with a net sale of 2,787. Other recent insider transactions involving Incyte Corp (INCY) include a net purchase of 2,510,403 shares made by Baker Bros. Advisors Lp , a net sale of 30,111 shares made by Vijay K Iyengar , and a net sale of 46,866 shares made by Barry P Flannelly .
In summary, during the past 3 months, insiders sold 97,842 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 97,842 shares. During the past 18 months, 209,240 shares of Incyte Corp (INCY) were sold and 2,510,403 shares were bought by its insiders, resulting in a net purchase of 2,301,163 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Thomas Tray Mailing Address
Above is the net worth, insider trading, and ownership report for Thomas Tray. You might contact Thomas Tray via mailing address: C/o Incyte Corporation, 1801 Augustine Cut-off, Wilmington De 19803.
